Gary H. Lyman

77.3k total citations · 36 hit papers
602 papers, 48.3k citations indexed

About

Gary H. Lyman is a scholar working on Oncology, Genetics and Economics and Econometrics. According to data from OpenAlex, Gary H. Lyman has authored 602 papers receiving a total of 48.3k indexed citations (citations by other indexed papers that have themselves been cited), including 382 papers in Oncology, 107 papers in Genetics and 105 papers in Economics and Econometrics. Recurrent topics in Gary H. Lyman's work include Neutropenia and Cancer Infections (223 papers), Cancer Treatment and Pharmacology (89 papers) and Blood disorders and treatments (84 papers). Gary H. Lyman is often cited by papers focused on Neutropenia and Cancer Infections (223 papers), Cancer Treatment and Pharmacology (89 papers) and Blood disorders and treatments (84 papers). Gary H. Lyman collaborates with scholars based in United States, Canada and United Kingdom. Gary H. Lyman's co-authors include Nicole M. Kuderer, Alok A. Khorana, David C. Dale, Eva Culakova, Jeffrey Crawford, Charles W. Francis, Lodovico Balducci, Mark R. Somerfield, Armando E. Giuliano and Leon E. Cosler and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Gary H. Lyman

588 papers receiving 46.9k citations

Hit Papers

Prognostic Factors Analysis of 17,600 Melanoma Patients: ... 1991 2026 2002 2014 2001 2008 2005 1991 2015 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System
    2001 1.8k citations Charles M. Balch, Kelly M. McMasters et al. Journal of Clinical Oncology profile →
  2. Development and validation of a predictive model for chemotherapy-associated thrombosis
    2008 1.5k citations Alok A. Khorana, Nicole M. Kuderer et al. profile →
  3. American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer
    2005 1.4k citations Gary H. Lyman, Mark R. Somerfield et al. Journal of Clinical Oncology profile →
  4. Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer
    1991 1.1k citations Gary H. Lyman, Mark G. Kris et al. profile →
  5. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014
    2015 968 citations Gary H. Lyman, Kari Bohlke et al. Journal of Clinical Oncology profile →
  6. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update
    2019 934 citations Nigel S. Key, Alok A. Khorana et al. Journal of Clinical Oncology profile →
  7. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)
    2018 855 citations Annie Young, Andrea Marshall et al. Journal of Clinical Oncology profile →
  8. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients
    2006 842 citations Nicole M. Kuderer, David C. Dale et al. Cancer profile →
  9. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
    2011 827 citations Ethan Basch, Ann Alexis Prestrud et al. Journal of Clinical Oncology profile →
  10. Recommendations on the Use of 18F-FDG PET in Oncology
    2008 790 citations Gary H. Lyman, Mark Gorman et al. profile →
  11. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
    2010 777 citations Gary H. Lyman et al. profile →
  12. Comorbidity and functional status are independent in older cancer patients.
    1998 764 citations Gary H. Lyman et al. Journal of Clinical Oncology profile →
  13. Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
    2014 762 citations Gary H. Lyman, Donald L. Weaver et al. Journal of Clinical Oncology profile →
  14. Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High‐Age Patients (CRASH) score
    2011 758 citations Gary H. Lyman et al. Cancer profile →
  15. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline
    2015 734 citations Carolyn D. Runowicz, Mandi L. Pratt‐Chapman et al. Journal of Clinical Oncology profile →
  16. American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer
    2007 723 citations Gary H. Lyman, Alok A. Khorana et al. Journal of Clinical Oncology profile →
  17. Chemotherapy‐induced neutropenia
    2004 643 citations David C. Dale, Gary H. Lyman et al. Cancer profile →
  18. Lymphatic mapping and sentinel lymph node biopsy in early‐stage breast carcinoma
    2005 620 citations Gary H. Lyman et al. Cancer profile →
  19. The Orderly Progression of Melanoma Nodal Metastases
    1994 602 citations Gary H. Lyman, Charles M. Balch et al. profile →
  20. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients
    2007 600 citations Alok A. Khorana, Eva Culakova et al. Cancer profile →
  21. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update
    2015 589 citations Kari Bohlke, Gary H. Lyman et al. Journal of Clinical Oncology profile →
  22. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
    2013 544 citations Gary H. Lyman, Alok A. Khorana et al. Journal of Clinical Oncology profile →
  23. Impact of Primary Prophylaxis With Granulocyte Colony-Stimulating Factor on Febrile Neutropenia and Mortality in Adult Cancer Patients Receiving Chemotherapy: A Systematic Review
    2007 517 citations Nicole M. Kuderer, David C. Dale et al. Journal of Clinical Oncology profile →
  24. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline
    2015 509 citations Carolyn D. Runowicz, Mandi L. Pratt‐Chapman et al. CA A Cancer Journal for Clinicians profile →
  25. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer
    2021 489 citations Gary H. Lyman, Marc Carrier et al. profile →
  26. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck.
    1992 465 citations Gary H. Lyman et al. Journal of Clinical Oncology profile →
  27. American Cancer Society Head and Neck Cancer Survivorship Care Guideline
    2016 444 citations Ezra E.W. Cohen, Samuel J. LaMonte et al. CA A Cancer Journal for Clinicians profile →
  28. Screening, Assessment, and Management of Fatigue in Adult Survivors of Cancer: An American Society of Clinical Oncology Clinical Practice Guideline Adaptation
    2014 442 citations Gary H. Lyman et al. Journal of Clinical Oncology profile →
  29. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
    2017 397 citations Paul J. Hesketh, Mark G. Kris et al. Journal of Clinical Oncology profile →
  30. Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
    2017 375 citations Gary H. Lyman, Mark R. Somerfield et al. Journal of Clinical Oncology profile →
  31. Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline
    2018 256 citations Gary H. Lyman, Kari Bohlke et al. Journal of Clinical Oncology profile →
  32. Antiemetics: ASCO Guideline Update
    2020 224 citations Paul J. Hesketh, Mark G. Kris et al. Journal of Clinical Oncology profile →
  33. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis
    2018 213 citations Ang Li, Gary H. Lyman et al. Thrombosis Research profile →
  34. Integrative Medicine for Pain Management in Oncology: Society for Integrative Oncology–ASCO Guideline
    2022 139 citations Gary H. Lyman et al. Journal of Clinical Oncology profile →
  35. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update
    2023 135 citations Nigel S. Key, Alok A. Khorana et al. Journal of Clinical Oncology profile →
  36. Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship
    2023 123 citations Maryam B. Lustberg, Nicole M. Kuderer et al. Nature Reviews Clinical Oncology profile →

Peers

Gary H. Lyman
Comparison fields: 5 of 203
  • Oncology 24.9k
  • Internal Medicine 8.7k
  • Surgery 7.7k
  • Cancer Research 6.8k
  • Pulmonary and Respiratory Medicine 6.3k
Replace John A. Baron with:
John A. Baron United States
Mark N. Levine Canada
Giuseppe Lippi Italy
Mark R. Somerfield United States
Daniel L. Clarke‐Pearson United States
Christine M. Lohse United States
Donna Neuberg United States
Børge G. Nordestgaard Denmark
Christopher R. Flowers United States
Hein Putter Netherlands
John A. Baron United States View profile →
Citations per field, relative to Gary H. Lyman
Gary H. Lyman · 1×
Citations per year, relative to Gary H. Lyman
Gary H. Lyman · 1×

Countries citing papers authored by Gary H. Lyman

Since Specialization
Citations

This map shows the geographic impact of Gary H. Lyman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary H. Lyman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary H. Lyman more than expected).

Fields of papers citing papers by Gary H. Lyman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary H. Lyman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary H. Lyman. The network helps show where Gary H. Lyman may publish in the future.

Co-authorship network of co-authors of Gary H. Lyman

This figure shows the co-authorship network connecting the top 25 collaborators of Gary H. Lyman. A scholar is included among the top collaborators of Gary H. Lyman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary H. Lyman. Gary H. Lyman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
Artificial Intelligence in Cancer Clinical Research: II. Development and Validation of Clinical Prediction Models
2024 ·Cancer Investigation ·Gary H. Lyman, Nicole M. Kuderer
0
2
Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer—Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update
2024 ·Journal of Clinical Oncology ·Rachel A. Freedman, Jennifer L. Caswell‐Jin, Michael J. Hassett, Mark R. Somerfield, Sharon H. Giordano, (unknown), Mariana Chávez‐MacGregor, Amy Comander, Zoneddy Dayao, Andrea Eisen, (unknown), Stephanie L. Graff, Tari A. King, Gary H. Lyman, (unknown), Cheryl Perkins, Melinda L. Telli, Maureen Trudeau, Antonio C. Wolff, (unknown)
18
3
Heterogeneity and Utility of Pharmaceutical Company Sharing of Individual-Participant Data Packages
2023 ·JAMA Oncology ·Ashley M. Hopkins, Natansh D. Modi, Ahmad Y. Abuhelwa, Ganessan Kichenadasse, Nicole M. Kuderer, Gary H. Lyman, Michael D. Wiese, Ross A. McKinnon, Frank W. Rockhold, (unknown), Andrew Rowland, Michael J. Sorich
11
4
Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship breakdown →
2023 ·Nature Reviews Clinical Oncology ·Maryam B. Lustberg, Nicole M. Kuderer, Aakash Desai, Cristiane Decat Bergerot, Gary H. Lyman
123
5
Intervention Nonadherence in the TrACER (S1415CD) Study: A Pragmatic Randomized Trial of a Standardized Order Entry for CSF Prescribing
2023 ·JCO Oncology Practice ·Dawn L. Hershman, Aasthaa Bansal, William E. Barlow, Kathryn B. Arnold, Kate Watabayashi, (unknown), Sean D. Sullivan, Gary H. Lyman, Scott D. Ramsey
1
6
An evaluation of stakeholder engagement in comparative effectiveness research: lessons learned from SWOG S1415CD
2022 ·Journal of Comparative Effectiveness Research ·(unknown), Kate Watabayashi, Karma L. Kreizenbeck, (unknown), Aasthaa Bansal, William E. Barlow, Gary H. Lyman, Dawn L. Hershman, (unknown), (unknown), (unknown), Jamie Myers, (unknown), (unknown), (unknown), (unknown), Jeffrey Crawford, Sean D. Sullivan
1
7
Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update
2021 ·Journal of Clinical Oncology ·Jennifer J. Griggs, Kari Bohlke, Edward P. Balaban, James J. Dignam, Evan Hall, R. Donald Harvey, (unknown), Kelsey Klute, Vicki A. Morrison, Tunghi May Pini, Gary L. Rosner, Carolyn D. Runowicz, Michelle Shayne, Alex Sparreboom, (unknown), Corrine Zarwan, Gary H. Lyman
75
8
Multicenter Study of Antibody Seroprevalence against COVID-19 in Patients Presenting to Iranian Cancer Centers after One Year of the COVID-19 Pandemic
2021 ·Cancer Investigation ·Seyed Alireza Javadinia, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Ahmad Ghasemi, Gary H. Lyman, James S. Welsh, (unknown), (unknown)
19
9
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Performance Status Work Group
2021 ·Clinical Cancer Research ·Allison Magnuson, Suanna S. Bruinooge, Harpreet Singh, Keith D. Wilner, Shadia I. Jalal, Stuart M. Lichtman, Paul G. Kluetz, Gary H. Lyman, Heidi D. Klepin, Mark E. Fleury, (unknown), Allen S. Melemed, Fernanda I. Arnaldez, Upal Roy, Caroline Schenkel, (unknown), Elizabeth Garrett‐Mayer
44
10
Adverse events among chronic myelogenous leukemia patients treated with tyrosine kinase inhibitors: a real-world analysis of health plan enrollees
2020 ·Leukemia & lymphoma ·Eric J. Chow, David R. Doody, Jennifer J. Wilkes, Laura Becker, Shasank Chennupati, Pamela Morin, Lena E. Winestone, Henry J. Henk, Gary H. Lyman
11
11
Mortality in hospitalized patients with cancer and coronavirus disease 2019: A systematic review and meta‐analysis of cohort studies
2020 ·Cancer ·Aakash Desai, Rohit Gupta, Shailesh Advani, Lara Ouellette, Nicole M. Kuderer, Gary H. Lyman, Ang Li
89
12
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update breakdown →
2019 ·Journal of Clinical Oncology ·Nigel S. Key, Alok A. Khorana, Nicole M. Kuderer, Kari Bohlke, Agnes Lee, Juan I. Arcelus, Sandra L. Wong, Edward P. Balaban, Christopher R. Flowers, Charles W. Francis, (unknown), Ajay K. Kakkar, Mark N. Levine, Howard A. Liebman, Margaret A. Tempero, Gary H. Lyman, Anna Falanga
934
13
Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D) breakdown →
2018 ·Journal of Clinical Oncology ·Annie Young, Andrea Marshall, (unknown), Oliver Chapman, Anand Lokare, Catherine St. Hill, Danielle Hale, Janet Dunn, Gary H. Lyman, Charles Hutchinson, Peter MacCallum, Ajay K. Kakkar, Richard Hobbs, Stavros Petrou, Jeremy Dale, Christopher Poole, Anthony Maraveyas, Mark N. Levine
855
14
Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial
2017 ·Thrombosis Research ·Alok A. Khorana, Charles W. Francis, Nicole M. Kuderer, Marc Carrier, Thomas L. Ortel, Ted Wun, Deborah J. Rubens, Susan K. Hobbs, Renuka Iyer, Derick R. Peterson, Andrea Baran, Katherine Kaproth-Joslin, Gary H. Lyman
96
15
American Cancer Society Head and Neck Cancer Survivorship Care Guideline breakdown →
2016 ·CA A Cancer Journal for Clinicians ·Ezra E.W. Cohen, Samuel J. LaMonte, (unknown), Kerry L. Beckman, Nader Sadeghi, Katherine A. Hutcheson, Michael D. Stubblefield, (unknown), Penelope Fisher, Kevin Stein, Gary H. Lyman, Mandi L. Pratt‐Chapman
444
16
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014 breakdown →
2015 ·Journal of Clinical Oncology ·Gary H. Lyman, Kari Bohlke, Alok A. Khorana, Nicole M. Kuderer, Agnes Y. Lee, Juan I. Arcelus, Edward P. Balaban, Jeffrey Clarke, Christopher R. Flowers, Charles W. Francis, (unknown), Ajay K. Kakkar, Nigel S. Key, Mark N. Levine, Howard A. Liebman, Margaret A. Tempero, Sandra L. Wong, Mark R. Somerfield, Anna Falanga
968
17
Sentinel Lymph Node Biopsy for Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Joint Clinical Practice Guideline
2012 ·Journal of Clinical Oncology ·Sandra L. Wong, Charles M. Balch, Patricia A. Hurley, Sanjiv S. Agarwala, Timothy Akhurst, Alistair J. Cochran, Janice N. Cormier, Mark Gorman, (unknown), Kelly M. McMasters, R. Dirk Noyes, Lynn M. Schuchter, Matías E. Valsecchi, Donald L. Weaver, Gary H. Lyman
239
18
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update breakdown →
2011 ·Journal of Clinical Oncology ·Ethan Basch, Ann Alexis Prestrud, Paul J. Hesketh, Mark G. Kris, Petra Feyer, Mark R. Somerfield, (unknown), Rebecca Clark-Snow, Anne Marie C. Flaherty, B Freundlich, Gary R. Morrow, Kamakshi V. Rao, Rowena Schwartz, Gary H. Lyman
827
19
Acute Myeloid Leukemia or Myelodysplastic Syndrome in Randomized Controlled Clinical Trials of Cancer Chemotherapy With Granulocyte Colony-Stimulating Factor: A Systematic Review
2010 ·Journal of Clinical Oncology ·Gary H. Lyman, David C. Dale, Debra A. Wolff, Eva Culakova, Marek S. Poniewierski, Nicole M. Kuderer, Jeffrey Crawford
111
20
Breast Cancer Screening: Science, Society and Common Sense
2009 ·Cancer Investigation ·Gary H. Lyman
9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by John A. Baron Breakdown of academic impact, for papers by Mark N. Levine Breakdown of academic impact, for papers by Giuseppe Lippi Breakdown of academic impact, for papers by Mark R. Somerfield Breakdown of academic impact, for papers by Daniel L. Clarke‐Pearson Breakdown of academic impact, for papers by Christine M. Lohse Breakdown of academic impact, for papers by Donna Neuberg Breakdown of academic impact, for papers by Børge G. Nordestgaard Breakdown of academic impact, for papers by Christopher R. Flowers Breakdown of academic impact, for papers by Hein Putter
Rankless by CCL
2026